Core Viewpoint - The company reported a total revenue of 10.81 billion RMB for the first three quarters of 2025, reflecting a year-on-year increase of 12.3%, with all business segments showing positive growth [1] Revenue Breakdown - The adult nutrition and care products segment saw a revenue increase of 6.0% year-on-year [1] - The infant nutrition and care products segment experienced a significant revenue growth of 24.0%, with infant formula revenue rising by 33.3% [1] - The pet nutrition and care products segment recorded a revenue increase of 8.2% year-on-year [1] Regional Performance - Domestic revenue for the adult nutrition and care segment grew by 15.7%, with cross-border e-commerce revenue increasing by 23.1% and Douyin revenue soaring by 77.7% [1] - Revenue from Australia declined by 19.4%, attributed to the company's proactive adjustment of purchasing channels, while local growth in Australia was 8.9% [1] - Other regions saw a revenue increase of 19%, mainly driven by high growth in nine emerging markets in Asia [1] Brand Performance - The company's brand, Biostime, achieved a market share of 16.4% in the ultra-premium infant formula market, with a quarterly share of 17.3% in Q3 2025 [1] - The decline in probiotic revenue has narrowed, likely due to new product promotions and the stabilization of pharmacy channels [1] Financial Position - The company ended Q3 2025 with a cash balance of 1.74 billion RMB after repaying 150 million RMB equivalent in USD debt, indicating a strong financial position [1] - Overall, the company is expected to maintain positive growth across multiple business segments, positioning itself as a long-term supplier of nutrition products for all family members [1] Profit Forecast - The company is projected to achieve a net profit attributable to shareholders of 518 million RMB, 672 million RMB, and 781 million RMB for 2025, 2026, and 2027, respectively, with corresponding PE ratios of 16, 12, and 11 times [2]

Investment Rating - The investment rating for H&H International Holdings is "Buy" and is maintained [6]. Core Views - In the first three quarters of 2025, the company reported total revenue of 10.81 billion RMB, reflecting a year-on-year increase of 12.3%. All business segments recorded positive growth, with the adult nutrition and care products segment increasing by 6.0%, the infant nutrition and care products segment by 24.0%, and the pet nutrition and care products segment by 8.2% [2][4][6]. Summary by Relevant Sections Revenue Performance - Total revenue for the first three quarters of 2025 was 10.81 billion RMB, up 12.3% year-on-year. The adult nutrition and care products segment saw a 6.0% increase, while the infant nutrition and care products segment grew by 24.0%. Specifically, infant formula revenue surged by 33.3%, and the decline in infant probiotics and nutritional supplements narrowed to 2.3%. The pet nutrition and care products segment also experienced an 8.2% increase [2][4][6]. Business Segment Analysis - The adult nutrition and care (ANC) segment's revenue increased by 6.0%, with domestic revenue rising by 15.7%. Cross-border e-commerce revenue grew by 23.1%, and Douyin revenue surged by 77.7%. However, Australian revenue declined by 19.4%, primarily due to the company's proactive adjustment of purchasing channels. In contrast, Australian local revenue increased by 8.9%, maintaining market leadership for the Swisse brand. Other regions saw a 19% revenue increase, driven by high growth in nine emerging Asian markets. The infant nutrition and care (BNC) segment's revenue rose by 24.0%, with infant formula revenue increasing by 33.3% (domestic revenue up 35.2%). The market share of the company's premium infant formula brand reached 16.4% in 2025 Q3, with a quarterly increase to 17.3%. The probiotics segment's revenue decline was mitigated by new product promotions and online channel stabilization. The pet nutrition and care (PNC) segment's revenue grew by 8.2%, with North American Zesty Paws revenue up 12.4%, while Solid Gold revenue fell by 18.3% due to channel and product structure adjustments. In China, pet nutrition revenue increased by 8.0%, with high-margin products rising to 33.7% [6]. Financial Position - The company has a strong cash position, with a cash balance of 1.74 billion RMB at the end of Q3 2025, following the early repayment of 150 million RMB equivalent in USD debt. Overall, the performance across multiple business segments is positive, indicating a favorable outlook for H&H as a supplier of nutritional products for all family members. The projected net profits for 2025, 2026, and 2027 are 518 million RMB, 672 million RMB, and 781 million RMB, respectively, corresponding to price-to-earnings ratios of 16, 12, and 11 times [6].

Core Insights - H&H International Holdings Limited reported a revenue of 10.805 billion yuan for the first nine months of 2025, representing a year-on-year growth of 12.3% [1] - The company’s three core business segments—Adult Nutrition and Care (ANC), Infant Nutrition and Care (BNC), and Pet Nutrition and Care (PNC)—all experienced growth, with China remaining the primary revenue source, accounting for 71.0% of total revenue, up 20.6% year-on-year [1] - The company aims to enhance scientific innovation investments to drive growth in adult nutrition, infant formula, and pet nutrition products while optimizing its capital structure [3] Business Segment Performance - ANC segment achieved a revenue of 5.24 billion yuan, growing by 6.0% year-on-year, with Swisse in China growing by 15.7%, driven mainly by e-commerce channels [1][2] - BNC segment revenue reached 3.97 billion yuan, up 24.0% year-on-year, with sales of infant formula in mainland China increasing by 35.2%, outperforming the overall market [2] - PNC segment generated 1.59 billion yuan in revenue, reflecting an 8.2% year-on-year growth, supported by an upgrade in pet consumption structure [2] Financial Health - The company has optimized its capital structure by repaying 300 million yuan (equivalent) of USD syndicated loans ahead of schedule, reducing debt levels and improving financing efficiency [2] - As of the end of September, the company maintained a cash reserve of 1.74 billion yuan, ensuring stable overall liquidity [2]

机构：中金公司 研究员：陈文博/王文丹 公司近况 公司公布3Q25 经营数据：9M25 收入108.1 亿元，同比+12%（按照同类比较基准增长12.3%）；其中 3Q25 收入37.9 亿元，同比+28.1%；经营数据超市场预期，主因婴配奶粉增长超预期。 评论 预计全年收入同比增长高单至低双，利润率有望保持健康水平。 我们预计公司全年收入有望实现同比高单至低双的增长，三大板块收入均将保持较好增长趋势；其中 ANC全年收入有望实现同比中至高单增长，BNC全年收入有望同比增长超20%，PNC全年收入有望同比 增长低双位数。利润端，我们预计公司25 年将维持健康的利润率水平，财务成本有望持续优化。 盈利预测与估值 考虑奶粉业务表现亮眼，上调25/26 年盈利预测5.1%/4.3%至6.7/7.9 亿元，公司当前交易于12/10 倍25/26 年P/E。维持目标价17.7 港币，对应16/13 倍25/26 年P/E和29%股价上行空间，维持跑赢行业评级。 风险 需求疲弱；竞争加剧；新品拓展不及预期；关税不确定性。 3Q25 BNC 婴配奶粉表现亮眼，ANC 及PNC 稳健增长。分业务看：1）BNC：3Q25 收入 ...

Group 1 - The core viewpoint of the report indicates that H&H International Holdings (01112) achieved a revenue of 10.805 billion yuan in Q1-3 of 2025, representing a year-on-year increase of 12.3%, with Q3 revenue reaching 3.786 billion yuan, up 28.5%, exceeding market expectations [1][3] - In terms of regional performance, the Chinese market accounted for 71.0% of total revenue in the first three quarters, showing a year-on-year growth of 20.6%. The Australia-New Zealand market declined by 19.4%, primarily due to a drop in purchasing agent business, while North America saw a growth of 5.9%, and other markets grew by 19.0%, with nine expanding Asian markets showing a remarkable growth of 64.4% [1] - The company's ANC (Adult Nutrition Category) business generated revenue of 5.243 billion yuan in Q1-3, up 6.0% year-on-year, with Q3 revenue of 1.804 billion yuan, increasing by 6.3%. Swisse maintained its position as the leading brand in the all-channel nutrition and health product market in mainland China, with a year-on-year revenue growth of 15.7% [1][3] Group 2 - The BNC (Baby Nutrition Category) revenue reached 3.973 billion yuan in Q1-3, reflecting a year-on-year increase of 24.0%, with Q3 revenue soaring to 1.471 billion yuan, up 90.6%. The significant growth in infant formula was attributed to the transition to new national standards and effective strategies in maternal education and channel investment [2] - The market share of the company's premium infant formula brand, Gan Shen Yuan, reached 16.4% in the first nine months, further increasing to 17.3% in Q3. Revenue from infant probiotics and nutritional products grew by 58.8% in Q3, with the decline in revenue narrowing to 2.3% over the first nine months [2] - The report anticipates that the EBITDA margin for the BNC business will rebound to 12%-15% due to strong growth in infant formula and the successful completion of the new national standard transition [2]

Core Viewpoint - H&H International Holdings (01112) reported strong Q3 performance with a 28.1% year-on-year revenue increase to HKD 3.79 billion, driven by exceptional growth in the BNC segment, particularly in infant formula [1][2] Performance Summary - For the first nine months of 2025, revenue reached HKD 10.81 billion, reflecting a 12% year-on-year increase, with Q3 revenue at HKD 3.79 billion, up 28.1% year-on-year, exceeding market expectations primarily due to infant formula growth [1][3] Segment Performance - **BNC (Infant Formula)**: Q3 revenue surged 90.6% to HKD 1.47 billion, with infant formula sales up 104% to HKD 1.23 billion. The market share in China's ultra-premium infant formula segment increased to 17.3% due to ongoing investments in maternal and e-commerce channels [2] - **ANC (Adult Nutrition)**: Q3 revenue grew 5.6% (6.3% on a comparable basis) to HKD 1.8 billion, with a 15.7% year-on-year increase in the China region, now accounting for 70.6% of total revenue. Cross-border e-commerce and Douyin channels showed significant growth [2] - **PNC (Pet Nutrition)**: Q3 revenue increased 7.3% to HKD 510 million, with steady performance in both China and North America [2] Future Outlook - The company is expected to achieve high single to low double-digit revenue growth in 2025, with all three segments maintaining positive growth trends. Profit margins are anticipated to remain healthy, supported by ongoing financial cost optimization [3] Earnings Forecast and Valuation - The earnings forecast for 2025 and 2026 has been raised by 5.1% and 4.3% to HKD 670 million and HKD 790 million, respectively. The current trading multiples are 12x and 10x for 2025 and 2026 P/E, with a target price of HKD 17.7, indicating a 29% upside potential [4]

Core Insights - The core point of the article is that Jianhe Group reported a significant increase in revenue and market share in the infant formula sector for the first nine months of 2025, indicating strong growth in the company's performance [1] Financial Performance - Jianhe Group achieved a revenue of 10.805 billion yuan for the first nine months of 2025, representing a year-on-year growth of 12.3% [1] - The sales revenue of infant formula in mainland China saw a substantial increase of 35.2% year-on-year during the reporting period [1] Market Position - In the third quarter, the market share of the ultra-premium infant formula brand, He Sheng Yuan, rose to 17.3%, marking a historical high for the company [1] - He Sheng Yuan's infant probiotic nutritional supplements also returned to double-digit growth, reflecting a positive trend in product demand [1]

Group 1: Market Overview - The Hang Seng Index fell by 0.45%, down 117 points, closing at 25,812 points, while the Hang Seng Tech Index dropped by 0.98% [1] - The trading volume in the Hong Kong stock market reached HKD 112.6 billion in the morning session [1] Group 2: Hydrogen Energy Sector - Hydrogen energy stocks experienced a significant rise, driven by the continuous rollout of green hydrogen ammonia industry policies, indicating a maturing industry [1] - Reshaping Energy (02570) surged by 24.29%, while Guofu Hydrogen Energy (02582) increased by over 4.64% [1] Group 3: Oil Sector - Oil stocks continued their recent upward trend, with institutions noting the resilience of the three major oil companies during the oil price downturn [1] - Sinopec (00386) rose by 3.6%, PetroChina (00857) increased by 2.49%, and CNOOC (00883) gained 2.11% [1] Group 4: Telecommunications and Technology - Changfei Optical Fiber and Cable (06869) saw an increase of over 4% after China Telecom completed the world's first ultra-long-distance hollow core fiber transmission experiment [1] - Boleton (01333) surged by over 10% as the company is set to globally launch its autonomous driving specialized mining truck this Friday [1] Group 5: Gold and Consumer Products - Shangshan Gold (01939) rose nearly 2% following a profit warning, which is expected to boost its global layout of intelligent gold terminals [1] - H&H International Holdings (01112) increased by over 2%, with a strong growth momentum in its infant-related products, particularly in infant formula sales exceeding industry averages [1] Group 6: Medical and Defense Sectors - Yimai Sunshine (02522) rose by over 4% as the company plans to further invest in Yinghe Medical, validating its commercial path for medical data assetization [1] - China Shipbuilding Defense (00317) increased by over 4%, with institutions noting that second-hand ship prices have surpassed new ship prices, indicating an upcoming positive trend in the shipbuilding sector [1] Group 7: Declining Stocks - Jacobson Pharmaceutical (02633) fell by over 8% due to a 5.36% year-on-year decrease in mid-term earnings, despite a 20% increase in dividends [2] - Yuejiang (02432) dropped by over 4%, accumulating a decline of over 40% in the past two months, having completed two rounds of equity financing in four months [2]

Core Viewpoint - H&H International Holdings (01112.HK) experienced a significant increase in stock price, rising over 4% to reach 13.7 HKD with a trading volume of 27.18 million HKD [1] Group 1 - The stock price of H&H International Holdings increased by 4.1% [1] - The current trading price is reported at 13.7 HKD [1] - The total trading volume reached 27.18 million HKD [1]

Core Viewpoint - H&H International Holdings (01112) reported a 12.0% year-on-year increase in total revenue for the nine months ending September 30, 2025, reaching RMB 10.805 billion, driven by strong growth in the infant nutrition and care products segment, particularly in infant formula milk powder, which saw a 33.3% increase [1][1][1] Group 1: Financial Performance - Total revenue increased by 12.0% year-on-year to RMB 10.805 billion, with a comparable basis increase of 12.3% [1][1][1] - The infant nutrition and care products segment experienced accelerated growth, with a 24.0% increase [1][1][1] - Infant formula milk powder business grew by 33.3% year-on-year [1][1][1] Group 2: Business Segment Insights - The infant probiotics and nutritional supplements segment saw a reduced decline of 2.3%, with a strong double-digit growth in the last three months of the reporting period [1][1][1] - The infant formula powder industry is currently under pressure due to demand factors, but H&H's sales in this segment increased by 10.0% year-on-year, outperforming the industry average [1][1][1] - Strong sales performance in Stage 1 and Stage 2 infant formula contributed to the company's growth [1][1][1] Group 3: Market Outlook - The ongoing implementation of childcare subsidy policies is expected to improve demand for infant formula, supporting continued growth for H&H's products [1][1][1] - The company’s infant probiotics and nutritional supplements are anticipated to gradually return to a growth trajectory [1][1][1]